The Pharma Data

DECEMBER 17, 2020

COVID-19 vaccine developers are faced with an ethical quandary — whether to let phase 3 trial participants become “unblinded” and to receive authorized vaccines as they become available, which could hinder the collection of meaningful trial data. Pfizer, which has received emergency approvals in the U.S.

Vaccine 52

Vaccine Trials Long-Term Care Facilities FDA 52

The Pharma Data

DECEMBER 2, 2020

2, 2020 – Britain became the first Western country to allow emergency use of a coronavirus vaccine on Wednesday, after approving Pfizer’s candidate in the race to inoculate millions of people around the globe. But there are daunting obstacles to the vaccine’s delivery to the masses. WEDNESDAY, Dec.

Vaccine 40

Vaccine Long-Term Care Facilities Hospitals Nurses 40

The Pharma Data

DECEMBER 4, 2020

Britain First to Approve Emergency Use of Pfizer’s COVID vaccine. Britain became the first Western country to allow emergency use of a coronavirus vaccine on Wednesday, approving Pfizer’s candidate in the race to inoculate millions of people around the globe.

Long-Term Care Facilities 52

Long-Term Care Facilities Vaccine Nurses Hospitals 52

The Pharma Data

DECEMBER 3, 2020

.” Britain First to Approve Emergency Use of Pfizer’s COVID vaccine. Britain became the first Western country to allow emergency use of a coronavirus vaccine on Wednesday, approving Pfizer’s candidate in the race to inoculate millions of people around the globe.

Hospitals 52

Hospitals Long-Term Care Facilities Vaccine Nurses 52

The Pharma Data

DECEMBER 21, 2020

A study published in the journal Cell Discovery back in March initially suggested that melatonin – and repurposing existing medicines in general – may be the key to regulating COVID-19 within the body. However, there are two vaccines that have been authorized in the U.S. Both vaccines require two doses, according to USA Today.

Long-Term Care Facilities 52

Long-Term Care Facilities Vaccine Virus Clinical Trials 52

The Pharma Data

OCTOBER 28, 2020

Discussions with global regulators are ongoing. Lilly scientists rapidly developed the antibody in less than three months after it was discovered by AbCellera and the scientists at the National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Center. patients who recovered from COVID-19. .

Government 40

Government Long-Term Care Facilities Hospitals Therapies 40

The Pharma Data

NOVEMBER 9, 2020

Lilly is in discussions with global regulators to make bamlanivimab available around the world. Lilly scientists rapidly developed the antibody in less than three months after it was discovered by AbCellera and the scientists at the National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Center.

Treatment 52

Treatment FDA Hospitals Long-Term Care Facilities 52